Holen Sie sich die Stockscreener-App
1.43
2.14%
0.03
Schlusskurs vom Vortag:
$1.40
Offen:
$1.45
24-Stunden-Volumen:
46,724
Relative Volume:
0.63
Marktkapitalisierung:
$144.03M
Einnahmen:
$68.15M
Nettoeinkommen (Verlust:
$-67.60M
KGV:
-2.1232
EPS:
-0.6735
Netto-Cashflow:
$-41.80M
1W Leistung:
-2.72%
1M Leistung:
-56.00%
6M Leistung:
-58.06%
1J Leistung:
-58.19%
1-Tages-Spanne:
$1.42
$1.4729
1-Wochen-Bereich:
$1.40
$1.525
52-Wochen-Spanne:
$1.25
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
1.43 | 148.06M | 68.15M | -67.60M | -41.80M | -0.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2022-05-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-03-06 | Herabstufung | Goldman | Neutral → Sell |
| 2019-10-30 | Fortgesetzt | Guggenheim | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Neutral |
| 2019-03-14 | Eingeleitet | William Blair | Outperform |
| 2018-12-19 | Eingeleitet | Goldman | Neutral |
| 2018-07-16 | Eingeleitet | Barclays | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2017-09-05 | Herabstufung | SunTrust | Buy → Hold |
| 2017-09-05 | Bestätigt | Wells Fargo | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-02-28 | Eingeleitet | Wells Fargo | Outperform |
| 2016-04-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Eingeleitet | BofA/Merrill | Buy |
| 2015-04-20 | Eingeleitet | Jefferies | Buy |
| 2015-04-20 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Cellectis Adr Aktie (CLLS) Neueste Nachrichten
Cellectis at Stifel 2026 Virtual Cardiometabolic Forum: pivot to in vivo editing - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
European ADRs Slip In US Trading As Biotech Splits - Finimize
European ADRs Rose Late Thursday Morning, Led By Biotech - Finimize
European ADRs Inched Up As Telecom And Biotech Led - Finimize
Cellectis stock tumbles after Barclays double downgrade - Investing.com
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
CLLS Stock Slides Toward 14-Month Low: Citizens Downgrades Cellectis After Cancer Pipeline Pivot - Stocktwits
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Sess - Benzinga
Cellectis organise une conférence téléphonique et un webcast le 14 septembre pour présenter un point d’activité - GlobeNewswire Inc.
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Cellectis (NASDAQ:CLLS): Is Its Latest Rally More Than Technical? - Kalkine Media
European ADRs Edged Higher As Biotech Led The Pack - Finimize
Cellectis earnings beat by $0.04, revenue fell short of estimates - Investing.com
Cellectis Reports Financial Results for the Second Quarter 2026 - Barchart.com
Cellectis S.A. Sponsored ADR Revenue Breakdown – LS:A14QZE - TradingView
European ADRs Traded Higher In US Morning Session - Finimize
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
European ADRs Jumped As Biotech Led The Pack - Finimize
Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A14QZE Forecast — Price Target — Prediction for 2027 - TradingView
Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS) - TradingView
symbol__ Stock Quote Price and Forecast - CNN
European ADRs Slip, Even As Biotech Names Edge Higher - Finimize
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - Barchart.com
Cellectis stock rises on FDA therapy designation - Investing.com
Cellectis stock rises on FDA therapy designation By Investing.com - Investing.com India
CLLS Stock Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill
Barclays initiates Cellectis stock with overweight, $9 target - Investing.com
CLLS - Finviz
Cellectis’s SWOT analysis: biotech stock shows promise in CAR-T therapy - Investing.com
CLLS Stock Price, Quote & Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - ChartMill
Cellectis Reports Financial Results for the First Quarter 2026 - ChartMill
TL ResistanceStock ScreenerCharts - Finviz
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - ChartMill
European ADRs Open Lower As Telecoms And Biotech Split - Finimize
Cellectis stock rating held at outperform on allogeneic platform - Investing.com
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - ChartMill
European ADRs Headed For A Strong Week In US Trading - Finimize
Finanzdaten der Cellectis Adr-Aktie (CLLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):